Umbrella review evaluates gabapentinoids for neuropathic pain, showing mixed results and concerns about quality.
Key Points
This umbrella review aims to evaluate the effectiveness and risks associated with gabapentinoids in managing neuropathic pain.
Included 22 systematic reviews and meta-analyses under PRISMA standards.
Quality assessed using the AMSTAR 2 instrument.
Focused on six types of neuropathic pain conditions.
Mirogabalin reduced lower limb neuropathic pain better than pregabalin.
Gabapentin and pregabalin linked to dizziness and somnolence predominantly.
Efficacy shown in diabetic peripheral neuropathic pain and cancer-related neuropathic pain, but limited confidence due to critically low quality of studies.